Ultimately, a plethora of different molecules have been proposed as CENPE inhibitor: Syntelin, PF-2771, and Compound-A were shown to inhibit CENPE motor domain [107–109]; but the most promising molecule is GSK923295 that has already finished phase I clinical trial for other types of cancers [110] and it was shown to be effective in MB [106]. Here, CENPE is linked to cancer.